We are live on ! Find out more
GSK icon

GSK
GSK

779 hedge funds and large institutions have $9.91B invested in GSK in 2017 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 282 increasing their positions, 267 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $142M | Put options by funds: $72.1M

6% more capital invested

Capital invested by funds: $9.34B → $9.91B (+$569M)

6% more repeat investments, than reductions

Existing positions increased: 282 | Existing positions reduced: 267

5% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 58

0.14% more ownership

Funds ownership: 3.6% → 3.74% (+0.14%)

0% more funds holding in top 10

Funds holding in top 10: 11 → 11 (0)

1% less funds holding

Funds holding: 787 → 779 (-8)

Holders
779
Holders Change
-8
Holders Change %
-1.02%
% of All Funds
19.42%
Holding in Top 10
11
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.27%
New
61
Increased
282
Reduced
267
Closed
58
Calls
$142M
Puts
$72.1M
Net Calls
+$69.9M
Net Calls Change
+$17.4M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$211M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$118M
3
Millennium Management
Millennium Management
New York
+$98.9M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$59.2M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$35.5M

Top Sellers

Rank Fund Capital Flow
1
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$248M
2
Ameriprise
Ameriprise
Minnesota
-$84.5M
3
MHI
Miller Howard Investments
New York
-$22.2M
4
Goldman Sachs
Goldman Sachs
New York
-$19.7M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$14.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$1.08B +$59.2M +1,111,391 +6%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$580M +$118M +2,217,867 +26%
Fisher Asset Management
3
Fisher Asset Management
Washington
$540M +$24.1M +451,615 +5%
Wells Fargo
4
Wells Fargo
California
$517M +$14M +261,917 +3%
State Street
5
State Street
Massachusetts
$446M -$6.6M -123,753 -1%
Renaissance Technologies
6
Renaissance Technologies
New York
$403M +$211M +3,948,720 +112%
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$390M +$14.6M +274,561 +4%
Hotchkis & Wiley Capital Management
8
Hotchkis & Wiley Capital Management
California
$338M +$13.8M +258,160 +4%
Bank of America
9
Bank of America
North Carolina
$329M +$33.3M +624,295 +11%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$253M -$2.33M -43,718 -0.9%
Federated Hermes
11
Federated Hermes
Pennsylvania
$195M +$35.5M +666,801 +23%
Morgan Stanley
12
Morgan Stanley
New York
$180M +$4.53M +84,932 +3%
RJA
13
Raymond James & Associates
Florida
$154M +$14.6M +273,437 +11%
BIP
14
Brandes Investment Partners
California
$145M -$104K -1,953 -0.1%
Northern Trust
15
Northern Trust
Illinois
$133M +$3.66M +68,664 +3%
Millennium Management
16
Millennium Management
New York
$123M +$98.9M +1,855,666 +442%
Goldman Sachs
17
Goldman Sachs
New York
$120M -$19.7M -369,726 -14%
Two Sigma Advisers
18
Two Sigma Advisers
New York
$118M +$15.7M +295,360 +16%
NIMC
19
NWQ Investment Management Company
California
$108M -$3.14M -58,917 -3%
EIC
20
Equity Investment Corp
Georgia
$108M -$12.7M -238,264 -11%
Macquarie Group
21
Macquarie Group
Australia
$106M -$3.78M -70,868 -3%
UBS Group
22
UBS Group
Switzerland
$94.3M +$1.41M +26,516 +2%
Two Sigma Investments
23
Two Sigma Investments
New York
$92.7M +$3.84M +71,953 +4%
SCCM
24
Schafer Cullen Capital Management
New York
$86.1M -$13.2M -246,841 -13%
CIM
25
Confluence Investment Management
Missouri
$83.2M +$5.99M +112,331 +8%
1
2 3 4 5

GSK Hedge Fund Activity: Q2 2017 in Review

779 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2017, worth a combined $9.91B — up 6.1% from $9.34B a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new GSK positions and 58 closed out — a net gain of 3 holders — while 282 added to existing stakes and 267 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $211M. The largest seller was Arrowstreet Capital, cutting an estimated $248M.

  • 779 institutional investors held GSK (GSK) as of Q2 2017, down from 787 in Q1 2017.
  • Funds reported $9.91B of GSK stock for Q2 2017, up 6.1% quarter-over-quarter.
  • 61 funds opened new GSK positions in Q2 2017 and 58 closed out, a net change of +3 holders.
  • The largest GSK buyer in Q2 2017 was Renaissance Technologies, an estimated $211M added.
  • The largest GSK seller in Q2 2017 was Arrowstreet Capital, an estimated $248M sold.

Based on aggregated 13F filings for Q2 2017.